EUVIMEDEUVIMED entdecken
Crossref

KidneyCure Transition to Independence Grants Have a Lasting Impact

Bridget M. Kuehn

Kidney News · 08.07.2026 · 18 (7) · 1-4

DOI: 10.62716/kn.003832026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kidney News, erschienen am 08.07.2026. Verfasst von Bridget M. Kuehn. Die Arbeit nennt 3 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

rant Bonebrake was 11 years old when he was diagnosed with Alport syndrome, a genetic disorder that causes kidney damage and other issues such as hearing loss.A couple of years later, when he participated in the first clinical trial for a drug for the syndrome, the study design was not optimal for an adolescent."As a patient, his greatest fear was dialysis, and the study site was at a dialysis center," so Grant had to walk past people receiving treatment, recalled his mother, Lisa Bonebrake, a member of the Kidney Health Initiative's (KHI's) Patient and Family Partnership Council (PFPC)."It really was not a wise choice for a study site for a young person," she acknowledged.In addition, during the very first appointment, the study coordinators collected more than 12 vials of blood, and Grant-who already had low blood pressure from taking angiotensin-converting enzyme inhibitors and angiotensin receptor blockerspassed out.The family shared their experience during KHI's Kidney Innovation Conference, held in May in Washington, DC, in which one of the themes was designing patient-friendly clinical studies.During a workshop, attendees heard from patients and learned about working with trusted community messengers, such as patient foundations for rare diseases, clinician-researchers, and local spiritual leaders; obtaining the patients' stories and wishes first-hand; and establishing patient advisory boards to improve study designs.Attendees also heard from patient organizations about the value of including patients from day 1.A big barrier in industry is not understanding how to involve patients in the process of clinical trial development, from stage 1 or in preclinical efforts, said Ms. Bonebrake, who is also executive director of the Alport Syndrome Foundation.PFPC is creating a map-type document, to be released by late 2027, explaining how to involve patients in all phases of development from the preclinical phase through postevaluation."We can definitely be helpful when it comes to introducing companies to the trusted experts in our disease

Zitieren

APA

Kuehn, B. M. (2026). KidneyCure Transition to Independence Grants Have a Lasting Impact. Kidney News, 18(7), 1-4. https://doi.org/10.62716/kn.003832026

Vancouver

Kuehn BM. KidneyCure Transition to Independence Grants Have a Lasting Impact. Kidney News. 2026;18(7):1-4. doi:10.62716/kn.003832026

BibTeX
@article{Kuehn2026,
  author = {Kuehn, Bridget M.},
  title = {KidneyCure Transition to Independence Grants Have a Lasting Impact},
  journal = {Kidney News},
  year = {2026},
  volume = {18},
  number = {7},
  pages = {1--4},
  doi = {10.62716/kn.003832026}
}
Kostenlos starten →